MX2020002078A - Composiciones de amantadina, preparaciones de estas y métodos de uso. - Google Patents

Composiciones de amantadina, preparaciones de estas y métodos de uso.

Info

Publication number
MX2020002078A
MX2020002078A MX2020002078A MX2020002078A MX2020002078A MX 2020002078 A MX2020002078 A MX 2020002078A MX 2020002078 A MX2020002078 A MX 2020002078A MX 2020002078 A MX2020002078 A MX 2020002078A MX 2020002078 A MX2020002078 A MX 2020002078A
Authority
MX
Mexico
Prior art keywords
amantadine
pharmaceutically acceptable
methods
acceptable salt
preparations
Prior art date
Application number
MX2020002078A
Other languages
English (en)
Inventor
Gregory T Went
Timothy J Fultz
Sangita Ghosh
Natalie Mcclure
Original Assignee
Adamas Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamas Pharma Llc filed Critical Adamas Pharma Llc
Publication of MX2020002078A publication Critical patent/MX2020002078A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proveen en la presente composiciones farmacéuticas orales que comprenden amantadina, o una sal farmacéuticamente aceptable de esta, y un excipiente farmacéuticamente aceptable, y que tienen un nivel bajo de solvente orgánico. También se proveen métodos para la administración oral de una composición que comprende amantadina, o una sal farmacéuticamente aceptable de esta, a un sujeto, la cual tiene efectos secundarios gastrointestinales o perturbaciones del sueño reducidos. Además, se proveen composiciones orales de liberación extendida que comprenden amantadina, o una sal farmacéuticamente aceptable de esta, que son adecuadas para administración una vez por día.
MX2020002078A 2017-08-24 2018-08-23 Composiciones de amantadina, preparaciones de estas y métodos de uso. MX2020002078A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762549921P 2017-08-24 2017-08-24
PCT/US2018/047754 WO2019040748A1 (en) 2017-08-24 2018-08-23 AMANTADINE COMPOSITIONS, THEIR PREPARATION, AND METHODS OF USE

Publications (1)

Publication Number Publication Date
MX2020002078A true MX2020002078A (es) 2020-09-21

Family

ID=65439620

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020002078A MX2020002078A (es) 2017-08-24 2018-08-23 Composiciones de amantadina, preparaciones de estas y métodos de uso.
MX2023012198A MX2023012198A (es) 2017-08-24 2020-02-21 Composiciones de amantadina, preparaciones de estas y metodos de uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023012198A MX2023012198A (es) 2017-08-24 2020-02-21 Composiciones de amantadina, preparaciones de estas y metodos de uso.

Country Status (10)

Country Link
US (3) US11077073B2 (es)
EP (1) EP3672581A4 (es)
JP (2) JP2020531543A (es)
CN (2) CN111372578A (es)
AU (2) AU2018320946B2 (es)
BR (1) BR112020003375A2 (es)
CA (1) CA3072764A1 (es)
IL (1) IL272834B2 (es)
MX (2) MX2020002078A (es)
WO (1) WO2019040748A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX365650B (es) 2009-12-02 2019-06-10 Adamas Pharmaceuticals Inc Composiciones de amantadina y metodos para su uso.
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
BR112020003375A2 (pt) 2017-08-24 2020-08-25 Adamas Pharma, Llc composições de amantadina, preparações das mesmas, e métodos de uso
US11441653B1 (en) 2021-05-20 2022-09-13 Dana Automotive Systems Group, Llc Integrated gearbox in electric motor systems

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
DK469989D0 (da) 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
US5221536A (en) 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5190763A (en) 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
DE4225730C2 (de) 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
US5358721A (en) 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
DE4413350A1 (de) 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
WO1997045091A2 (en) 1996-05-31 1997-12-04 Euro-Celtique, S.A. Sustained release oxycodone formulations with no fed/fast effect
US5849800A (en) 1997-03-28 1998-12-15 The Penn State Research Foundation Use of amantadine for treatment of Hepatitis C
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
PE20000728A1 (es) 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CA2393601A1 (en) 1999-12-09 2001-06-14 Alza Corporation Antiviral medication
AU2002252364B2 (en) 2001-03-13 2005-08-25 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
US20060198815A1 (en) 2001-03-19 2006-09-07 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained release
DE10129265A1 (de) 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
CA2454200A1 (en) 2001-07-17 2003-01-30 Teva Pharmaceutical Industries Ltd. Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
US20030045577A1 (en) 2001-08-15 2003-03-06 Madhat Maher N. Method for preventing infectious respiratory diseases
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
CA2493301A1 (en) 2002-07-29 2004-02-12 Glaxo Group Limited Sustained release formulations comprising lamotrigine
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US6913768B2 (en) 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
US20040121010A1 (en) 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20060024366A1 (en) 2002-10-25 2006-02-02 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
AU2003301121A1 (en) 2002-12-18 2004-07-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
AR043467A1 (es) 2003-03-05 2005-07-27 Osmotica Argentina S A Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson
MXPA06003100A (es) 2003-09-19 2006-06-20 Penwest Pharmaceuticals Co Formas de dosis de liberacion retardada.
WO2005027843A2 (en) 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
US20050119249A1 (en) 2003-12-02 2005-06-02 Erik Buntinx Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
WO2005072125A2 (en) 2004-01-16 2005-08-11 Massachusetts Institute Of Technology Composite materials for controlled release of water soluble products
AU2005209310B2 (en) 2004-01-29 2011-01-06 Neuromolecular, Inc. Combination of a NMDA receptor antagonist and a MAO-inhibitor or a GADPH-inhibitor for the treatment of central nervous system-related conditions
WO2005079773A2 (en) 2004-02-13 2005-09-01 Neuromolecular, Inc. Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
ES2337700T3 (es) 2004-02-18 2010-04-28 Sepracor, Inc. Terapia combinada de agonista de dopamina con sedantes para mejorar la calidad del sueño.
WO2006009769A1 (en) 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
JP2006079138A (ja) 2004-09-07 2006-03-23 Ricoh Co Ltd ステータス取得方法、プリンタドライバ及び情報処理装置
RU2404750C2 (ru) 2004-11-23 2010-11-27 Адамас Фармасьютикалс, Инк. Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту
US20190008799A1 (en) 2004-11-23 2019-01-10 Adamas Pharma, Llc Composition for administering an nmda receptor antagonist to a subject
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
WO2006058236A2 (en) 2004-11-24 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
US20190328684A1 (en) 2004-11-24 2019-10-31 Adamas Pharma, Llc Composition and method for treating neurological disease
US8252331B2 (en) 2004-12-03 2012-08-28 Osmotica Kereskedelmi és Szolgáltató, KFT Osmotic device containing amantadine and an osmotic salt
US8574626B2 (en) 2004-12-03 2013-11-05 Osmotica Kereskedelmi és Szolgáltató KFT Osmotic device containing amantadine and an osmotic salt
AR053986A1 (es) * 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
US20080279819A1 (en) 2005-02-15 2008-11-13 Adamas Pharmaceuticals, Inc. Combinations Therapy for Treatment of Demyelinating Conditions
CA2604052C (en) 2005-04-06 2014-07-08 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of cns-related conditions
US20060280795A1 (en) 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
US8920837B2 (en) 2005-07-01 2014-12-30 Rubicon Research Private Limited Sustained release dosage form
RU2385712C2 (ru) 2005-08-24 2010-04-10 Рубикон Рисёч Пвт Лтд. Рецептура с контролируемым высвобождением
WO2007056424A2 (en) 2005-11-07 2007-05-18 Penwest Pharmaceuticals, Co. Controlled-release emulsion compositions
US20080089861A1 (en) 2006-07-10 2008-04-17 Went Gregory T Combination therapy for treatment of demyelinating conditions
KR101575679B1 (ko) 2006-08-30 2015-12-08 자고텍 아게 코어 및 하나 이상의 배리어 층을 포함하는 방출 제어형 경구 투여 제제
EP1961414A1 (en) 2007-02-21 2008-08-27 FUJIFILM Manufacturing Europe B.V. A controlled release composition comprising a recombinant gelatin
EP2129683A4 (en) * 2007-02-26 2011-01-05 Ironwood Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATMENT OF HEART FAILURE AND OTHER DISORDERS
US7981930B2 (en) 2007-03-13 2011-07-19 Adamas Pharmaceuticals, Inc. Compositions and kits for treating influenza
GB2448224B (en) 2007-04-02 2010-09-01 Parkinson S Inst Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent
EP1987815A1 (en) 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
CA2689101C (en) 2007-05-30 2013-01-22 Neos Therapeutics, Lp Modifying drug release in suspensions of ionic resin systems
US8247438B2 (en) * 2008-02-27 2012-08-21 Neuropill, Inc. Methods for treating schizophrenia
US20110142905A1 (en) 2008-08-14 2011-06-16 Bioneer A/S Coated tablets with remaining degradation surface over the time
US20100221328A1 (en) * 2008-12-31 2010-09-02 Wertz Christian F Sustained-release formulations
US20130059008A1 (en) 2009-01-23 2013-03-07 Jeffrey L. Atkinson Drying methods for tuning microparticle properties
KR101571198B1 (ko) 2009-03-18 2015-11-23 에보니크 룀 게엠베하 중성 비닐 중합체 및 부형제를 포함하는 코팅을 이용하는, 에탄올의 영향에 대한 내성을 갖는 제어 방출 제약 조성물
CA2756386C (en) 2009-03-23 2019-01-15 Micell Technologies, Inc. Drug delivery medical device
CA2757337A1 (en) 2009-04-03 2010-10-07 Coating Place, Inc. Modified-release pharmaceutical drug composition
MX365650B (es) 2009-12-02 2019-06-10 Adamas Pharmaceuticals Inc Composiciones de amantadina y metodos para su uso.
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
US8895662B2 (en) 2010-12-31 2014-11-25 Eternal Chemical Co., Ltd. Curable composition and method for manufacturing the same
US20130236544A1 (en) * 2012-03-08 2013-09-12 Dr. Reddy's Laboratories Ltd. Stable pharmaceutical compositions of fesoterodine
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
PL3215132T3 (pl) * 2014-11-04 2021-10-11 Adamas Pharmaceuticals, Inc. Amantadyna do poprawy chodu w stwardnieniu rozsianym
BR112020003375A2 (pt) 2017-08-24 2020-08-25 Adamas Pharma, Llc composições de amantadina, preparações das mesmas, e métodos de uso

Also Published As

Publication number Publication date
JP2023009251A (ja) 2023-01-19
BR112020003375A2 (pt) 2020-08-25
US11065213B2 (en) 2021-07-20
IL272834B1 (en) 2024-04-01
AU2018320946B2 (en) 2024-05-02
US11077073B2 (en) 2021-08-03
IL272834A (en) 2020-04-30
IL272834B2 (en) 2024-08-01
EP3672581A1 (en) 2020-07-01
CN117860718A (zh) 2024-04-12
AU2018320946A1 (en) 2020-04-16
EP3672581A4 (en) 2021-05-19
CN111372578A (zh) 2020-07-03
US20220117914A1 (en) 2022-04-21
US20190262285A1 (en) 2019-08-29
US20200069614A1 (en) 2020-03-05
AU2024205201A1 (en) 2024-08-15
MX2023012198A (es) 2023-10-25
JP2020531543A (ja) 2020-11-05
CA3072764A1 (en) 2019-02-28
WO2019040748A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
MX2023012198A (es) Composiciones de amantadina, preparaciones de estas y metodos de uso.
NZ747259A (en) Soluble c5ar antagonists
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
MX2016006053A (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
PH12016501310A1 (en) Pharmaceutical compositions comprising azd9291
WO2018165404A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
MX369121B (es) Formulacion farmaceutica acuosa de tapentadol para administracion oral.
JO3619B1 (ar) صياغات مثبطة للمناعة
TN2015000135A1 (en) Modified release formulations for oprozomib
EP3400964A4 (en) TASTE-MASKED AND ORAL ADMINISTRATIVE PHARMACEUTICAL PREPARATION WITH VARENICLIN OR PHARMACEUTICAL SALT OF IT
EA036036B1 (ru) Композиции, содержащие циклоспорин
PH12021551086A1 (en) Pharmaceutical formulations of cyclosporine analogs
WO2015125152A3 (en) Pharmaceutical compositions of asenapine
MX2022013450A (es) Formulaciones farmaceuticas.
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
TR201721700A2 (tr) Saksagli̇pti̇ni̇n ağizda dağilan formülasyonlari
MX370184B (es) Composición farmacéutica que comprende fingolimod.
TR201722323A2 (tr) Dabi̇gatranin oral farmasöti̇k kompozi̇syonlari
WO2013054178A3 (en) Extended release pharmaceutical compositions containing carmabazepine
WO2019151966A3 (en) Pharmaceutical tablet compositions of dabigatran
EA201891136A1 (ru) Фармацевтическая композиция, содержащая в качестве активного ингредиента производное 7-азаиндолин-2-она или его фармацевтически приемлемую соль
IN2015MU00907A (es)
WO2016187595A3 (en) Oral pharmaceutical composition of methylergonovine
ES2422657A1 (es) Composición farmacéutica sólida de cilostazol